All Pharma News
price-trendAsk Us
CAR-T therapy safe for relapsed or refractory T-cell malignancies, finds study

CAR-T therapy safe for relapsed or refractory T-cell malignancies, finds study
Catherine Eckford EUROPEANPHARMACEUTICALREVIEW
30 Sep 2022
Share Share
Bioheng Biotech Announces Publication of Impressive Results CD7-targeted CAR-T

Bioheng Biotech Announces Publication of Impressive Results CD7-targeted CAR-T
BIOSPACE
26 Sep 2022
Share Share
Bioheng`s CTB001 received ODD from the U.S. FDA

Bioheng`s CTB001 received ODD from the U.S. FDA
PRNEWSWIRE
28 Jan 2022
Share Share
US FDA grants orphan drug designation to Bioheng Biotech’s CTD401 to treat T-ALL

US FDA grants orphan drug designation to Bioheng Biotech’s CTD401 to treat T-ALL
PHARMABIZ
22 Jun 2021
Share Share